Nail incorporation kinetics of terbinafine in onychomycosis patients.
Patients with toe-nail onychomycosis were treated with terbinafine (250 mg daily, n = 20) for either 6 or 12 weeks in a randomized double-blind study. Plasma and distal nail clippings were taken before initiation of therapy and 1, 6, 12, 18, 24, 36 and 48 weeks thereafter. Analytical data of terbinafine extracted from nail clippings or plasma were obtained by high-performance liquid chromatography (HPLC). Nail extracts and isolated HPLC terbinafine peaks were analysed using a combined gas chromatography-mass spectroscopy system (GC-MS) for unequivocal identification of the drug. Terbinafine could be detected in the distal nail in the majority of the patients within 1 week of starting therapy. Maximum terbinafine levels of 0.52 and 1.01 micrograms/g were measured after 18 weeks in the 6- and 12-week treatment groups, respectively. While plasma levels decreased rapidly after termination of therapy terbinafine was detected in the nails as long as 30 weeks (6 weeks treatment) and 36 weeks (12 weeks treatment) after termination of therapy at a range of 0.28-0.19 microgram/g. The drug concentrations measured at all time points are well above the minimum inhibitory concentration (MIC) for dermatophytes and other fungi. These data suggest that the drug reaches the nail plate rapidly and persists there for several months after cessation of active treatment.
Schatz
F
F
Dermatology Department, Sandoz Forschungsinstitut, Vienna, Austria.
Bräutigam
M
M
Dobrowolski
E
E
Effendy
I
I
Haberl
H
H
Mensing
H
H
Weidinger
G
G
Stütz
A
A
D000935:Antifungal Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004311:Double-Blind Method; D005533:Foot Dermatoses / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D009281:Naphthalenes / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014009:Onychomycosis / Q000188:drug therapy / Q000378:metabolism*; D000077291:Terbinafine
D000935:Antifungal Agents; D009281:Naphthalenes; D000077291:Terbinafine